SCHEMBL5540103

SCHEMBL5540103

CC(=O)N(c1ccccc1)c1ccc([O])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.52
KMT2A Q03164 4/20 0.49
MEN1 O00255 2/20 0.49
TSHR P16473 2/20 0.49
NPC1 O15118 2/20 0.47
APAF1 O14727 2/20 0.47
ALDH1A1 P00352 4/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
HDAC6 Q9UBN7 2/20 0.43
ATM Q13315 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TDP2 O95551 1/20 0.42
NSD2 O96028 1/20 0.42
CASP3 P42574 1/20 0.42
CACNA1B Q00975 1/20 0.42
APBA1 Q02410 1/20 0.42
HKDC1 Q2TB90 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8044893 0.91 NPSR1 (0.61) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL741752 0.89 NPSR1 (0.64) NPSR1KMT2AMEN1TSHRNPC1
Hydrochloric Acid SCHEMBL8550497 0.87 NPSR1 (0.61) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL1471487 0.85 NPSR1 (0.54) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL3975700 0.83 NPSR1 (0.52) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL8009586 0.82 NPSR1 (0.50) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL7526392 0.82 S100A4 (0.56) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL5605036 0.82 NPC1 (0.54) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL197621 0.82 NPSR1 (0.56) NPSR1KMT2AMEN1TSHRNPC1
SCHEMBL27583970 0.82 NPC1 (0.54) NPSR1KMT2AMEN1TSHRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NPSR1 747/4885KMT2A 4267/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.